2021.12.07
In 2021, Elpiscience Biopharma, Ltd. and TRIGR Therapeutics Inc. (acquired by Compass Therapeutics, Inc.) announced that they had reached an agreement on the exclusive development and commercialization rights of a bispecific antibody drug in Greater China.
Elpiscience Biopharma, Ltd. is a Chinese biomedical company committed to developing a new generation of innovative drugs for tumor immunotherapy. TRIGR is an American biomedical company focusing on the treatment of tumors with anti-angiogenesis and immunomodulation.
JunHe was entrusted by Elpiscience Biopharma, Ltd. to draft the license agreement in the project, and led the subsequent negotiation and modification of the agreement. JunHe provided the project with high-quality, rigorous and efficient professional legal services during the whole transaction process, which has been highly praised by the clients.
This project was led by Ph. D. Wang, Zhaohui (Zoe), and it was managed by Partner Mr. Zhao, Hao (Gerry).
